New UK Biotech could treat Diabetes with Lab-grown Cells

18/05/2016 - 3 minutes

Islexa is the new baby of Catapult and the University of Aberdeen, which will be developing laboratory grown islets. This could replace insulin production in patients with type 1 diabetes.

catapult_islexa_aberdeen_islet_diabetesOne of the coolest Biotechs in London, Catapult has joined the University of Aberdeen to create a new Biotech that could revolutionize treatment of type 1 diabetes (T1D).

Islexa is built on research from University of Aberdeen, which looked into re-programming normal pancreatic tissue into fully functional islets – clusters of cells that produce insulin.

This technology could offer an alternative to patients with T1D. In this type of diabetes, the immune system attacks the cells that produce insulin – one example of harmful inflammation.

Islexa’s laboratory grown islets are meant to bring islet transplants to more diabetes patients. While this procedure has shown efficacy, there is a shortage of suitable donor organs – and the extraction of islets is also complicated.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!

Support Us

Become a Member